---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-006229"
form_type: "8-K"
ticker: "MNPR"
cik: "0001645469"
company_name: "Monopar Therapeutics"
filed_at: "2026-03-02T23:59:59+00:00"
generated_at: "2026-05-15T22:40:35.793222+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Monopar appoints Susan Rodriguez as Chief Commercial and Strategy Officer; NDA submission planned H1 2026

## Summary
- Susan Rodriguez appointed Chief Commercial and Strategy Officer, effective March 2, 2026.
- She will lead commercial strategy ahead of planned NDA submission for ALXN1840 (Wilson disease) in H1 2026.
- Ms. Rodriguez previously was COO of Avadel, acquired by Alkermes for over $2 billion.
- She also served as CCO of Ardelyx, establishing its first commercial organization and launching two therapies.
- Over 30 years of biopharma leadership; holds MS/BS from University of Pennsylvania.

## SEC filing metadata
- accession: 0001437749-26-006229
- form_type: 8-K
- ticker: MNPR
- cik: 0001645469
- company_name: Monopar Therapeutics
- filed_at: 2026-03-02T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645469/000143774926006229/0001437749-26-006229-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645469/000143774926006229/mnpr20260302_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-006229
- JSON: https://secwatch.observer/filing/0001437749-26-006229.json
- Plain text: https://secwatch.observer/filing/0001437749-26-006229.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.